[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-venous-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-venous-disease":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,82,117,144,165],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100649487","ruscus-evaluation-for-symptom-control-in-uncomplicated-chronic-venous-insufficiency-100649487",false,"NCT07737236","Ruscus Evaluation for Symptom Control in Uncomplicated Chronic Venous Insufficiency","Evaluation of the Effects of Ruscus Aculeatus L. on Clinical Course and Quality of Life, and Assessment of Treatment Adherence and Tolerability in the Treatment of Chronic Venous Insufficiency: A Multicenter, Prospective, Observational Study","RESCUE-CVI","Inclusion Criteria:\n\n* Adults aged 18 to 75 years.\n* Patients prescribed Ruscus aculeatus L. as part of routine clinical practice, with the baseline visit performed within 7 days after treatment initiation.\n* Symptomatic chronic venous disease classified as CEAP (2020) C1-C6.\n* Willing and able to provide written informed consent and complete study as sessments.\n\nExclusion Criteria:\n\n* Symptomatic patients classified as CEAP C0.\n* Uncontrolled hypertension.\n* Lower extremity dermatitis or ulcer related to peripheral arterial disease or diabetes.\n* Neurological or orthopedic conditions limiting mobility or independent walking.\n* Active systemic infection.\n* Known malignancy or ongoing chemotherapy.\n* Acute deep vein thrombosis or acute superficial vein thrombosis.\n* Cognitive or physical conditions preventing participation in routine follow-up visits.\n* Pregnant or breastfeeding women.","ALL","18 Years","75 Years",{"count":21,"type":22},564,"ESTIMATED","OBSERVATIONAL","This multicenter, prospective, observational study aims to generate and analyze real-world data on the effectiveness and safety of Ruscus aculeatus L. treatment in patients with symptomatic chronic venous disease classified as CEAP C1-C6. Patients receiving Ruscus aculeatus L. as part of routine clinical practice will be followed for 90 days without any study-mandated intervention. Disease severity will be assessed using the revised Venous Clinical Severity Score (rVCSS), pain using the Visual Analog Scale (VAS), quality of life using the Chronic Venous Disease Quality of Life Questionnaire (CIVIQ-20), treatment adherence using the Visual Analog Scale for adherence (VAS-U), and safety through the collection of adverse events during the observation period.",[26],"Chronic Venous Disease",[26,28,29,30,31],"Ruscus aculeatus","CEAP Classification","rVCSS","CIVIQ-20","RECRUITING","2026-07-30",{"date":35,"type":36},"2026-07-31","ACTUAL",{"date":38,"type":36},"2026-06-02",{"date":40,"type":22},"2027-06-01",{"name":42,"class":43},"Turkish Society for Vascular and Endovascular Surgery","OTHER",25,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":55,"studyType":23,"phases":4,"briefSummary":56,"conditions":57,"keywords":64,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":4},"100633674","the-recana-for-lower-extremity-venous-obstructions-and-in-stent-restenosis-registry-100633674","NCT07529756","The ReCAna for Lower ExtremIty Venous OBstructions and In-StEnt Restenosis Registry","The ReCAna for Lower ExtremIty Venous OBstructions and In-StEnt Restenosis Registry (\"The CALIBER Registry\")","CALIBER","INCLUSION CRITERA:\n\nA. Native Vessel:\n\n1. INC-1: Subject is 18 years or older\n2. INC-2: Proximal lower extremity obstruction\u002Focclusion involving the femoral, common femoral, iliac veins, or inferior vena cava (IVC), alone or in combination that in the opinion of the investigator, treatment with the Recana would benefit the patient\n3. INC-3: Recana Thrombectomy Catheter System must enter vasculature\n4. INC-4: Willing and able to provide written informed consent\n\nB. In-Stent Restenosis:\n\n1. INC-1: Subject is 18 years or older\n2. INC-2: Subjects with stents implanted greater than 6 weeks prior to index procedure\n3. INC-3: Location of thrombosed stents in proximal lower extremity deep vein segments including common femoral, external iliac, common iliac vein, or inferior vena cava alone or in combination that in the opinion of the investigator treatment with the Recana would benefit the patient\n4. INC-4: Recana Thrombectomy Catheter System must enter vasculature\n5. INC-5: Willing and able to provide written informed consent\n\nEXCLUSION CRITERA\n\nA. Native Vessel:\n\n1. EXC-1: IVC aplasia\u002Fhypoplasia or other congenital anatomic anomalies of the IVC or iliac veins\n2. EXC-2: IVC filter in place at the time of index procedure that, in the judgment of the investigator, may interfere with the procedure\n3. EXC-3: Congenital anatomic anomalies of the iliac veins that in the opinion of the investigator would preclude treatment with the Recana\n4. EXC-4: Heparin allergy or hypersensitivity that cannot be adequately managed with alternate anticoagulant during or after the procedure, or prior diagnosis of HIT (Heparin-Induced Thrombocytopenia)\n5. EXC-5: Severe, life-threatening allergy to iodine or contrast dye\n6. EXC-6: Any contraindication to anticoagulants or antiplatelets that, in the opinion of the Investigator, cannot be medically managed throughout the study period\n7. EXC-7: Life expectancy less than 1 year\n8. EXC-8: Chronic non-ambulatory status such as long-term wheelchair requirement or bedridden status\n9. EXC-9: Known hypercoagulable states that, in the opinion of the investigator, cannot be medically managed throughout the study period\n10. EXC-10: Inability to secure venous access and cross lesion\n11. EXC-11: Subject has any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the subject\n12. EXC-12: Current active participation in another investigational drug or device study in which the primary endpoint has not been analyzed\n\nB. In-Stent Restenosis:\n\n1. EXC-1: Exposed stents with broken struts, significantly deformed struts, struts protruding into the vessel\n2. EXC-2: Stent failure caused by undersizing or malapposition of the stent(s) \\[For example, the segment of a stent in the iliac vein that is not wall apposed or cannot be apposed to the wall after balloon dilation is excluded. The segment of a stent that extends into the IVC that is not wall apposed would not be excluded.\\]\n3. EXC-3: Stents compressed to \\\u003C6mm that remain \\\u003C6mm after balloon dilation\n4. EXC-4: IVC filter in place at the time of index procedure that, in the judgment of the investigator, may interfere with the procedure\n5. EXC-5: Congenital anatomic anomalies of the iliac veins that in the opinion of the investigator would preclude treatment with the Recana\n6. EXC-6: Heparin allergy or hypersensitivity that cannot be adequately managed with alternate anticoagulant during or after the procedure, or prior diagnosis of HIT (Heparin-Induced Thrombocytopenia)\n7. EXC-7: Severe, life-threatening allergy to iodine or contrast dye\n8. EXC-8: Any contraindication to anticoagulants or antiplatelets that, in the opinion of the Investigator, cannot be medically managed throughout the study period\n9. EXC-9: Life expectancy less than 1 year\n10. EXC-10: Chronic non-ambulatory status such as long-term wheelchair requirement or bedridden status\n11. EXC-11: Known hypercoagulable states that, in the opinion of the Investigator, cannot be medically managed throughout the study period\n12. EXC-12: Inability to secure venous access and cross lesion\n13. EXC-13: Subject has any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the subject\n14. EXC-14: Current active participation in another investigational drug or device study in which the primary endpoint has not been analyzed",{"count":54,"type":22},500,"1 Year","The goal of this observational study is to gather additional safety and performance (effectiveness) data on the device for the treatment of symptomatic lower extremity venous obstructions and occlusions. The main questions the study aims to answer are:\n\n* What is the observed rate of safety events through the 30-day follow-up?\n* What is the rate of technical success (acute procedural success) achieved at the index procedure?\n\nParticipants already undergoing treatment with the Recana as part of their regular medical care will be followed for 1 year.",[26,58,59,60,61,62,63],"Chronic Venous Insufficiency, CVI","Venous Thrombosis","Thrombosis (Stent Thrombosis)","Thrombosis, Venous","Embolism and Thrombosis","Thrombectomy",[65,66,67,68,69,70,71],"in-stent restenosis","venous obstruction or occlusion","thrombus","emboli","CALIBER Registry","recanalization","debulking","NOT_YET_RECRUITING",{"date":74,"type":36},"2026-08-03",{"date":76,"type":22},"2026-08",{"date":78,"type":22},"2029-03",{"name":80,"class":81},"Intervene, Inc.","INDUSTRY",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":101,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":111,"completionDateStruct":112,"leadSponsor":114,"locationsCount":116},"100602421","effect-of-photobiomodulation-on-healing-of-venous-leg-ulcers-100602421","NCT07123285","Effect of Photobiomodulation on Healing of Venous Leg Ulcers","Effect of Photobiomodulation on the Healing of Lower-Limb Venous Ulcers: A Randomized, Double-Blind, Controlled Clinical Trial","Inclusion Criteria\n\n* Participants of either sex.\n* Age 19 to 85 years.\n* Lower-limb venous ulcer present for at least 6 weeks and not healed.\n* Ulcer without infection at enrollment.\n\nOperational confirmation before enrollment:\n\n* Venous etiology confirmed by Doppler ultrasonography demonstrating venous reflux.\n* Ankle-Brachial Index ≥0.8 to exclude concomitant arterial disease.\n* Written informed consent.\n\nExclusion Criteria\n\n* Ulcer of non-venous etiology.\n* Pregnancy.\n* Severe lower-limb arterial disease.\n* Current use or initiation of another venous-ulcer treatment different from the study treatment.\n\nProtocol Discontinuation Criteria\n\n* Wound worsening with onset of infection.\n* Any complication during the procedure requiring discontinuation for participant safety.","19 Years","85 Years",{"count":92,"type":22},102,"INTERVENTIONAL",[95],"NA","Venous leg ulcers are a significant public health problem because of their prolonged duration, high recurrence rates, and economic, social, and quality-of-life effects. Compression therapy is the standard treatment; however, healing may remain slow. Photobiomodulation is being investigated as an adjunctive treatment to promote tissue repair and wound healing.\n\nThis prospective, randomized, controlled, double-blind clinical trial will evaluate the efficacy of photobiomodulation combined with compression therapy in the healing of lower-limb venous leg ulcers. A total of 102 participants will be randomly allocated in a 1:1 ratio to an Experimental Group (n=51), receiving active photobiomodulation plus compression therapy, or a Control Group (n=51), receiving sham photobiomodulation plus compression therapy. Treatment will be administered twice weekly on Mondays and Thursdays for 16 weeks, totaling 32 sessions.\n\nThe primary outcome will be the percentage reduction in wound volume over 16 weeks, estimated from wound area and depth. Secondary outcomes will include percentage reduction in wound area, change in wound depth, complete wound healing, adverse events, wound quality assessed using the Bates-Jensen Wound Assessment Tool, pain intensity and rescue analgesic use, health-related quality of life assessed using the SF-36, clinical severity assessed using the Venous Clinical Severity Score, and direct treatment costs. Wound area will be measured using the ImitoWound® application.",[98,99,100,26],"Venous Leg Ulcer (VLU)","Venous Hypertension Ulcers","Chronic Venous Insufficiency",[102,103,104,105,106,107,108],"venous ulcers","photobiomodulation","Low-Level Laser Therapy","Compression Therapy","Venous Ulcer","Venous Leg Ulcer","Wound Healing","2026-07-28",{"date":33,"type":36},{"date":76,"type":22},{"date":113,"type":22},"2027-07",{"name":115,"class":43},"University of Nove de Julho",1,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":125,"sex":17,"minAge":18,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":93,"phases":129,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":4},"100647022","phase-3-randomized-placebo-crontrolled-clinical-trial-evaluating-the-efficacy-and-safety-of-heparan-sulfate-120-mg-prolonged-release-tablets-compared-with-placebo-in-patients-with-chronic-venous-disease-100647022","NCT07684833","Randomized, Placebo-crontrolled Clinical Trial Evaluating the Efficacy and Safety of Heparan Sulfate 120 mg Prolonged-Release Tablets Compared With Placebo in Patients With Chronic Venous Disease","Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate Efficacy and Safety of CLR-07-23 (Heparan Sulfate 120 mg Prolonged-release Tablets) in the Treatment of Primary Chronic Venous Disease","CLR-18","Inclusion Criteria:\n\n* Participants with an age ≥ 18 and ≤ 80 years\n* Diagnosed primary venous disease of the lower limbs in stage C2 - C5 according to the CEAP classification, involvement of the venous system of the lower limbs is verified by duplex ultrasonography\n* Presence of objective signs and subjective symptoms of the disease (classified according to rVCSS score ≥ 4)\n* Participants not using or planning to use compression therapy by their own decision\n* Provision of written informed consent as approved by the Ethics Committee (EC).\n\nExclusion Criteria:\n\n* Use of a venoactive drug in the last month\n* Regular use of compression therapy or use of mechanical devices for reduction of edema in the last month\n* Heart Failure (NYHA class III and IV), congestive heart failure with peripheral edema\n* eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m² at screening or chronic kidney disease documented in the medical history\n* ALT or AST more than 3 times the upper limit of normal range at screening or advanced liver disease documented in the medical history\n* Deep venous thrombosis lower limb thrombosis and \u002F or documented residual venous obstruction or deep venous reflux due to post-thrombotic alterations in the deep venous system\n* Superficial venous thrombosis of the lower limbs in the previous 6 months\n* Congenital venous\u002Flymphatic malformation\n* Neuropathy of any aetiology\n* Diabetic foot syndrome\n* Refractory (uncontrollable) hypertension (inability to therapeutically achieve a systolic blood pressure ≤ 160 mmHg or a diastolic blood pressure ≤ 100 mmHg)\n* Symptomatic ischemic disease of lower limbs\n* Lymphoedema: primary, posttraumatic, postoperative, post-radiation, malignant\n* Manual\u002Finstrumental lymphatic drainage in the last 3 months\n* Invasive procedure on the lower limbs in the last 6 months\n* Trauma of the lower extremity that has not fully healed\n* Use of oral\u002Fparenteral anticoagulants\n* Use of dual antiplatelet therapy\n* Use of loop diuretics\n* Use of oestrogens or progesterone and its derivates\n\n  -. Use of oral\u002Fparental corticosteroids in the last 6 weeks\n* Chronic pain treatment ≥ 14 days\n* Use of psychopharmaceuticals affecting fluid retention (antipsychotics, combined antidepressants)\n* Severe obesity (BMI \\> 40 kg\u002Fm2)\n* Participants with active malignant disease or malignant disease in remission for less than 5 years\n* Myeloproliferative or immune disorders\n* Contraindications to the IMP\u002FPlacebo administration\n* Hypersensitivity to the IMP\u002FPlacebo excipients. General Conditions\n* Pregnant or breastfeeding women\n* Women of child-bearing potential not using at least one effective contraceptive method for the entire trial\n* Participation in other investigational drug or device clinical trials within 30 days prior to study screening\n\n  -. Participants legally or mentally incapacitated unable to give informed consent for the participation in this trial\n* Participants unable or unwilling to comply with appointments or all protocol requirements.",true,"80 Years",{"count":128,"type":22},174,[130],"PHASE3","This multicenter, randomized, double-blind study is a phase III evaluates the safety and effectiveness of CLR prolonged-release tablets in patients with chronic venous insufficiency, has been shown to be effective in reducing the symptoms of itching, edema, spontaneous pain, and night cramps chronic venous disease.",[26,133,134],"Vein Disease","Venous Insufficiency of Leg","2026-06-29",{"date":137,"type":36},"2026-07-06",{"date":139,"type":22},"2026-11",{"date":141,"type":22},"2027-05",{"name":143,"class":81},"Barbara Maglione",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":93,"phases":153,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":4},"100580227","mobile-phone-thermal-imaging-assessment-of-incompetent-perforator-veins-100580227","NCT06834555","Mobile Phone Thermal Imaging Assessment of Incompetent Perforator Veins","Can Mobile Phone Thermal Imaging Provide an Ambulatory Assessment of Incompetent Perforator Veins?","Inclusion Criteria:\n\nA diagnosis of CVD by vascular surgeon, classified C0 to C6 according to CEAP (Clinical-Etiology - Anatomy - Pathophysiology) No history of lower extremity surgery The body mass index (BMI) is 18 to 35 kg\u002Fm2\n\nExclusion Criteria:\n\ndeep vein thrombosis heart disease peripheral artery disease chronic liver disease chronic kidney disease pregnancy severe obesity (BMI ≥35 kg\u002Fm2)",{"count":152,"type":22},100,[95],"Chronic venous disease is a common disease of the lower limbs. Severe CVD can lead to lower limb swelling, pigmentation, and repeated skin ulceration, which seriously affects patients' quality of life. About 10.5% to 92.7% of CVD patients with recurrent varicose veins had insufficient perforating veins. Treatment of these IPVs can promote venous ulcer healing and reduce the recurrence rate of venous ulcers. Accurate assessment and positioning of insufficient perforating veins in the lower leg is a key step in developing a personalized treatment strategy. At present, Color Doppler ultrasonography performed in the upright position in combination with the Valsalva maneuver or local pressure of the limb is regarded as the \"gold standard\" for the diagnosis of perforating veins insufficiency. However, in China, a large number of perforating veins insufficiency are diagnosed by venography. Because the majority of Chinese vascular surgeons are not versatile in vascular ultrasound examination and venous ultrasound protocols vary from institution to institution. A non-functioning valve in an insufficient perforated vein allows blood to flow retrograde from a deep vein to a superficial vein. Some researchers have shown that the venous blood temperature of deep veins is higher than that of superficial veins. Thus, the retrograde flow of \"warm blood\" from the deep vein to the superficial vein increases the skin temperature located on the insufficient perforated vein. This study tested the feasibility of a smartphone and its compatible portable thermal imaging device as a tool for assessing insufficient perforated vein. The objective is to study the sensitivity and specificity of smartphone thermal imaging in diagnosing and locating the insufficient perforated vein in CVD patients.",[26],"2025-02-13",{"date":158,"type":36},"2025-02-19",{"date":160,"type":22},"2025-03-01",{"date":162,"type":22},"2025-12-01",{"name":164,"class":43},"Guangdong Second Provincial General Hospital",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":4},"100540603","outcomes-of-different-treatment-options-in-chronic-venous-disease-100540603","NCT06318988","Outcomes of Different Treatment Options in Chronic Venous Disease","An Observational, Prospective Study to Assess the Outcomes of Different Treatment Options in Patients With Chronic Venous Disease in Belgium","VOS","Inclusion Criteria:\n\n\\* Patient visiting a GP with complaints related to CVD,\n\n* Patient receiving the diagnosis of CVD from the GP during the V0, according to international guidelines and made on a clinical basis,\n* Patient requiring and agreeing to receive conservative or invasive treatment,\n* French or Dutch speaking patient,\n* Patient signed informed consent and agrees to take part in the study and follow-up.\n\nExclusion Criteria:\n\n* Patient with coagulation disorders such as thrombophilia and\u002For taking anticoagulation drugs,\n* Pregnant or breastfeeding patient,\n* Patient with severe Peripheral Arterial Occlusive Disease (POAD), with Ankle Brachial Index (ABI) \\\u003C 0.8,\n* Patient with malignancy,\n* Patient with neurological disorder or dementia,\n* Patients taking regular treatment for CVD 3 months prior to inclusion (except painkillers or anti-inflammatory drugs if taken for reasons other than CVD),\n* Patient in any other clinical study for any pharmaceutical product within 4 weeks preceding study inclusion,\n* Patient with any comorbidity or situation preventing a follow-up of 2 years.",{"count":174,"type":22},2000,"This study aims to describe conservative and invasive treatments for patients with chronic venous disease (CVD) in Belgium, and their association with clinical and patient-reported outcomes during a follow-up of 24 months.",[26],"2024-06-27",{"date":179,"type":36},"2024-06-28",{"date":181,"type":22},"2024-07-01",{"date":183,"type":22},"2027-05-01",{"name":185,"class":43},"Universitaire Ziekenhuizen KU Leuven"]